Effect of bevacizumab on angiogenesis and related cytokines in mice with malignant pleural effusion
10.13699/j.cnki.1001-6821.2018.08.008
- VernacularTitle:贝伐单抗对肺癌恶性胸腔积液模型小鼠血管生成及相关细胞因子的影响
- Author:
Da-Peng ZHU
1
;
Peng GUO
;
Bi-Jun YU
;
Jian-Ying ZHOU
Author Information
1. 浙江省肿瘤医院 内镜中心
- Keywords:
lung cancer;
malignant pleural effusion;
bevacizumab;
vascular endothelial growth factor;
immunity
- From:
The Chinese Journal of Clinical Pharmacology
2018;34(8):942-944,960
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of bevacizumab on angiogenesis and related cytokines in model mice with malignant pleural effusion (PE).Methods The mouse model of lung cancer with malignant PE were established by pleural injection of Lewis lung cancer cells.Mouse were randomly divided into model group,cisplatin group,bevacizumab group,conbination group (bevacizumab combined with cisplatin),and health mouse as normal group.Mouse in model group were intraperitoneally injected with 0.9 ％ NaCl 0.4 mL;mouse in cisplatin group were intraperitoneal injected with cisplatin 5 mg · kg-1;mouse in bevacizumab group was injected with bevacizumab 15 mg · kg-1;mouse in the combination group were intraperitoneally injected with the two drugs (5 mg · kg-1 + 15 mg · kg-1),2 times per a week for 2 weeks.The survival time and PE in four groups were compared.The contents of vascular endothelial growth factor-A (VEGF-A),interleukin-2 (IL-2) in malignant PE of mouse in all groups were detected by enzyme linked immunosorbent assay.Results After dosing,the survival time in mouse of the model group,cisplatin group,bevacizumab group,and combination group were (11.76 ± 1.34),(14.35 ± 1.56),(16.65 ± 2.12),(18.42 ± 2.35) d,respectively;the a mount of PE in the four groups were (1.12 ± 0.24),(0.89 ± 0.20),(0.74 ± 0.22),(0.56 ± 0.25) mL respectively.The level of VEGF-A in the four groups were (625.45 ± 72.52),(454.25 ± 55.14),(265.25 ± 32.21),(205.25 ± 25.54) pg · mL-1,respectively.The level of IL-2 in the four groups were (70.12 ± 8.45),(56.45 ±6.52),(130.12 ± 15.45),(110.24 ±12.36)pg · mL-1,respectively.Comparison between drugs groups and model group on the factors,the differences were significant (P ＜ 0.05,P ＜ 0.01).Conclusion Bevacizumab can reduce the amount of PE and prolong the survival time of the model mouse with malignant PE.
